Symbiosis Pharmaceutical Services Completes Successful Sterile Inspection

Article

The company’s Scotland-based facility has successfully completed a scheduled inspection by the UK’s MHRA; there were no critical or major observations noted.

Symbiosis Pharmaceutical Services, a CMO in parenteral manufacturing, announced that its Scotland-based facility has successfully completed a scheduled inspection by the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA). There were no critical or major observations noted.

Symbiosis has been re-inspected and approved for the ongoing production of investigational medicinal products for clinical trials. The company has received confirmation of continued authorization for the GMP manufacture of aseptically-filled licensed commercial products following initial approval of the commercial manufacturer’s/importers license in 2014.

Source: Symbiosis Pharmaceutical Services

Recent Videos
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development
Related Content